PE20230304A1 - Derivados de glucagon como agentes hipoglucemicos y antiobesidad - Google Patents

Derivados de glucagon como agentes hipoglucemicos y antiobesidad

Info

Publication number
PE20230304A1
PE20230304A1 PE2022001996A PE2022001996A PE20230304A1 PE 20230304 A1 PE20230304 A1 PE 20230304A1 PE 2022001996 A PE2022001996 A PE 2022001996A PE 2022001996 A PE2022001996 A PE 2022001996A PE 20230304 A1 PE20230304 A1 PE 20230304A1
Authority
PE
Peru
Prior art keywords
glucagon
present
hypoglycemic
obesity agents
hypoglycemia
Prior art date
Application number
PE2022001996A
Other languages
English (en)
Inventor
Jung Kuk Kim
Jong Min Lee
Sang Yun Kim
Sung Min Bae
Sung Youb Jung
Se Chang Kwon
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of PE20230304A1 publication Critical patent/PE20230304A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion se refiere a un nuevo peptido derivado del glucagon y a una composicion para la prevencion o el tratamiento de hipoglucemia, que contiene el nuevo peptido derivado del glucagon como principio activo. El derivado de glucagon de acuerdo con la presente invencion tiene propiedades fisicas mejoradas debido al cambio en el punto isoelectrico (pI) mientras que es capaz de mantener una actividad en los receptores del glucagon y, por tanto, puede mejorar la conformidad del paciente cuando se usa como un agente hipoglucemico y tambien es adecuado para la administracion en combinacion con otros agentes antiobesidad. Por consiguiente, el derivado de glucagon de acuerdo con la presente invencion se puede usar de manera eficaz para la prevencion y el tratamiento de la hipoglucemia y la obesidad.
PE2022001996A 2014-12-30 2015-12-30 Derivados de glucagon como agentes hipoglucemicos y antiobesidad PE20230304A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140193800 2014-12-30
PCT/KR2015/014422 WO2016108586A1 (ko) 2014-12-30 2015-12-30 안정성이 증가된 글루카곤 유도체

Publications (1)

Publication Number Publication Date
PE20230304A1 true PE20230304A1 (es) 2023-02-13

Family

ID=56284642

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2022001996A PE20230304A1 (es) 2014-12-30 2015-12-30 Derivados de glucagon como agentes hipoglucemicos y antiobesidad
PE2017001168A PE20171154A1 (es) 2014-12-30 2015-12-30 Derivados de glucagon con estabilidad mejorada

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2017001168A PE20171154A1 (es) 2014-12-30 2015-12-30 Derivados de glucagon con estabilidad mejorada

Country Status (29)

Country Link
US (1) US11135271B2 (es)
EP (2) EP3241841A4 (es)
JP (2) JP6797122B2 (es)
KR (1) KR102291020B1 (es)
CN (1) CN107636009B (es)
AR (1) AR103322A1 (es)
AU (1) AU2015372818A1 (es)
CA (1) CA2972748A1 (es)
CL (1) CL2017001718A1 (es)
CO (1) CO2017006308A2 (es)
CR (1) CR20170293A (es)
DO (1) DOP2017000156A (es)
EA (1) EA035527B1 (es)
EC (1) ECSP17040923A (es)
ES (1) ES2976562T3 (es)
GT (1) GT201700150A (es)
HK (1) HK1248713A1 (es)
IL (2) IL253206B (es)
MA (1) MA40709B1 (es)
MX (1) MX2017008569A (es)
MY (1) MY185334A (es)
PE (2) PE20230304A1 (es)
PH (1) PH12017501222A1 (es)
SG (1) SG11201705376SA (es)
TN (1) TN2017000271A1 (es)
TW (1) TW201639878A (es)
UA (1) UA126960C2 (es)
WO (1) WO2016108586A1 (es)
ZA (1) ZA201705015B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230304A1 (es) * 2014-12-30 2023-02-13 Hanmi Pharm Ind Co Ltd Derivados de glucagon como agentes hipoglucemicos y antiobesidad
HUE066226T2 (hu) 2015-06-30 2024-07-28 Hanmi Pharmaceutical Co Ltd Glükagon származék és annak hosszú hatású konjugátumát tartalmazó készítmény
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
CA3010265A1 (en) 2015-12-31 2017-07-06 Hanmi Pharm. Co., Ltd. Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
IL263934B2 (en) * 2016-06-29 2023-10-01 Hanmi Pharm Ind Co Ltd A derivative of glucagon, its conjugate, a preparation containing it and its medical use
BR112019016077A2 (pt) 2017-02-03 2020-03-31 Hanmi Pharm. Co., Ltd. Conjugado da fórmula 1, método para preparar o conjugado, preparação de atuação longa, preparação para prevenir ou tratar diabetes e método para tratar diabetes
AR113430A1 (es) * 2017-12-22 2020-04-29 Hanmi Pharm Ind Co Ltd Proteína de fusión enzimática terapéutica que tiene una nueva estructura y su uso
WO2019147718A1 (en) * 2018-01-23 2019-08-01 Xeris Pharmaceuticals, Inc. Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon
AU2019405389A1 (en) * 2018-12-21 2021-06-24 Hanmi Pharm. Co., Ltd. Pharmaceutical composition containing insulin and glucagon
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
IL298396A (en) 2020-05-22 2023-01-01 Hanmi Pharm Ind Co Ltd A liquid formulation of a long-acting conjugate of a glucagon derivative
WO2022015082A1 (ko) 2020-07-15 2022-01-20 한미약품 주식회사 글루카곤 유도체 또는 이의 결합체의 간질환에 대한 치료적 용도
JP2024512895A (ja) 2021-04-09 2024-03-21 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン誘導体を含む慢性腎臓疾患予防又は治療用薬学組成物
KR20230095666A (ko) 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 물질 및 이의 용도
CN115490760B (zh) * 2022-07-04 2023-04-14 北京惠之衡生物科技有限公司 一种glp-1受体和gcg受体共激动多肽衍生物

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
GB9423277D0 (en) 1994-11-18 1995-01-11 Univ Nottingham Pulsed laser deposition of coatings
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
JP2005501058A (ja) 2001-07-31 2005-01-13 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ Ｇｌｐ−１、ｅｘｅｎｄｉｎ−４、そのペプチド・アナログ及びその使用
ES2390270T3 (es) 2003-03-19 2012-11-08 Eli Lilly And Company Compuestos de GLP-1 unidos a polietilenglicol
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US7736653B2 (en) 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier
US8288339B2 (en) 2006-04-20 2012-10-16 Amgen Inc. GLP-1 compounds
WO2008086086A2 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
WO2008101017A2 (en) 2007-02-15 2008-08-21 Indiana Unversity Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
KR20100049032A (ko) 2007-06-19 2010-05-11 오츠카 가가쿠 가부시키가이샤 당사슬 부가 ｇｌｐ―１ 펩티드
US8895694B2 (en) 2007-09-05 2014-11-25 Novo Nordisk A/S Glucagon-Like Peptide-1 derivatives and their pharmaceutical use
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
EP2300035B1 (en) 2008-06-17 2015-08-12 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
WO2010096052A1 (en) * 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
PE20120914A1 (es) 2009-06-16 2012-08-22 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip
CA2767792A1 (en) 2009-07-13 2011-01-20 Zealand Pharma A/S Acylated glucagon analogues
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
AU2011206979B2 (en) 2010-01-20 2015-09-10 Zealand Pharma A/S Treatment of cardiac conditions
CN102918056B (zh) 2010-03-26 2016-08-10 诺沃—诺迪斯克有限公司 新的胰高血糖素类似物
CA2797089A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
MX2013006304A (es) 2010-12-22 2013-07-02 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben actividad del receptor gip.
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
KR102011924B1 (ko) 2011-05-18 2019-08-21 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약
DK3878859T5 (da) 2011-06-10 2024-06-10 Hanmi Science Co Ltd Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende disse
CN109306015B (zh) * 2011-06-17 2022-04-26 韩美科学株式会社 包括泌酸调节肽和免疫球蛋白片段的结合物以及其应用
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
KR20140097151A (ko) * 2011-11-17 2014-08-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
CA2877358A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
MX356000B (es) 2012-06-21 2018-05-08 Hoffmann La Roche Analogos de glucagon que exhiben actividad del receptor gip.
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
DK2916819T3 (da) 2012-11-06 2019-10-14 Hanmi Pharm Ind Co Ltd Væskeformig formulering af proteinkonjugat omfattende oxyntomodulinet og et immunoglobulin-fragment
CN118324870A (zh) 2012-11-20 2024-07-12 梅德瑞斯糖尿病有限责任公司 用于胰岛素抗性的改良的肽药物
US10005817B2 (en) 2012-11-20 2018-06-26 Eumederis Pharmaceuticals, Inc. Peptide pharmaceuticals
PE20151239A1 (es) 2012-12-21 2015-09-08 Sanofi Sa Derivados de exendina-4 funcionalizada
MX362275B (es) 2013-04-18 2019-01-10 Novo Nordisk As Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
KR102418477B1 (ko) * 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
PE20230304A1 (es) 2014-12-30 2023-02-13 Hanmi Pharm Ind Co Ltd Derivados de glucagon como agentes hipoglucemicos y antiobesidad
HUE066226T2 (hu) 2015-06-30 2024-07-28 Hanmi Pharmaceutical Co Ltd Glükagon származék és annak hosszú hatású konjugátumát tartalmazó készítmény
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
CA3010265A1 (en) 2015-12-31 2017-07-06 Hanmi Pharm. Co., Ltd. Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist

Also Published As

Publication number Publication date
JP2020188819A (ja) 2020-11-26
MA40709B1 (fr) 2019-07-31
JP6797122B2 (ja) 2020-12-09
SG11201705376SA (en) 2017-08-30
CO2017006308A2 (es) 2017-09-29
EP3575314A3 (en) 2020-01-22
CL2017001718A1 (es) 2018-01-12
DOP2017000156A (es) 2017-10-15
NZ770767A (en) 2024-04-26
CN107636009A (zh) 2018-01-26
KR20160082482A (ko) 2016-07-08
ZA201705015B (en) 2018-04-25
EP3575314C0 (en) 2024-02-14
EA035527B1 (ru) 2020-06-30
US11135271B2 (en) 2021-10-05
IL253206A0 (en) 2017-08-31
EP3575314B1 (en) 2024-02-14
CN107636009B (zh) 2021-04-16
TW201639878A (zh) 2016-11-16
TN2017000271A1 (en) 2018-10-19
MY185334A (en) 2021-05-06
AU2015372818A1 (en) 2017-07-27
EP3575314A2 (en) 2019-12-04
NZ733464A (en) 2024-01-26
IL281375B (en) 2021-10-31
CR20170293A (es) 2017-11-03
EP3241841A4 (en) 2018-10-17
GT201700150A (es) 2018-12-12
AR103322A1 (es) 2017-05-03
EP3241841A1 (en) 2017-11-08
JP7079301B2 (ja) 2022-06-01
IL281375A (en) 2021-04-29
WO2016108586A1 (ko) 2016-07-07
JP2018504901A (ja) 2018-02-22
ECSP17040923A (es) 2017-12-01
ES2976562T3 (es) 2024-08-05
EA201791333A1 (ru) 2017-12-29
MX2017008569A (es) 2017-10-20
IL253206B (en) 2021-10-31
MA40709A1 (fr) 2017-12-29
UA126960C2 (uk) 2023-03-01
CA2972748A1 (en) 2016-07-07
KR102291020B1 (ko) 2021-08-20
PH12017501222A1 (en) 2018-01-15
US20170360892A1 (en) 2017-12-21
PE20171154A1 (es) 2017-08-16
HK1248713A1 (zh) 2018-10-19
BR112017014205A2 (pt) 2018-03-06

Similar Documents

Publication Publication Date Title
CO2017006308A2 (es) Derivados de glucagón
CL2018000684A1 (es) Moduladores de la proteína de núcleo de la hepatitis b.
PE20180449A1 (es) Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
ECSP19021223A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CL2019001465A1 (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip.
DOP2016000233A (es) MODULADORES ALOSTÉRICOS DE PROTElNA NÚCLEO DE HEPATITIS B
CR20120345A (es) Derivados de 3-hidroxi-5-arilisotiazol novedosos
UA118558C2 (uk) Пептидна сполука
CL2016002372A1 (es) Cenicriviroc para el tratamiento de la fibrosis.
CR20160367A (es) Compuesto heterocíclico fusionado
CL2016003075A1 (es) Composición para tratar diabetes, que contiene un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
GT201500293A (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2015002698A1 (es) Nuevos compuestos y composiciones para la inhibicion de fasn
CO2019009215A2 (es) Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c
BR112018067731A2 (pt) coagonistas de glucagon e glp-1 para o tratamento de obesidade
CL2017002031A1 (es) Formulación en polvo nasal para el tratamiento de hipoglicemia
CR20170314A (es) Formulación de relación fija de insulina glargina/lixisenatida
AR128158A2 (es) Compuesto heterocíclico
UY35774A (es) Compuesto heterocíclico
AR103323A1 (es) Derivados de glucagón
CL2017002293A1 (es) Tratamiento de pacientes con diabetes mellitus de tipo 2
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2017001843A1 (es) Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2.
CO2017004785A2 (es) N-[4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il]-2-metilpiridin-5-carboxamida o una sal farmacéutica como antagonista del receptor a2a